Financials data is unavailable for this security.
View more
Year on year Harbin Pharmaceutical Group Co Ltd had net income fall -14.88% from 464.36m to 395.26m despite a 11.93% increase in revenues from 13.81bn to 15.46bn. An increase in the selling, general and administrative costs as a percentage of sales from 18.34% to 20.37% was a component in the falling net income despite rising revenues.
| Gross margin | 27.66% |
|---|---|
| Net profit margin | 3.88% |
| Operating margin | 5.20% |
| Return on assets | 4.40% |
|---|---|
| Return on equity | 11.63% |
| Return on investment | 11.75% |
More ▼
Cash flow in CNYView more
In 2023, Harbin Pharmaceutical Group Co Ltd increased its cash reserves by 43.21%, or 891.89m. The company earned 949.67m from its operations for a Cash Flow Margin of 6.14%. In addition the company generated 147.94m cash from financing while 206.64m was spent on investing.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 2.00 |
|---|---|
| Tangible book value per share | 1.80 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.32 |
|---|---|
| Quick ratio | 1.08 |
| Total debt/total equity | 0.9439 |
|---|---|
| Total debt/total capital | 0.4524 |
More ▼
Growth rates in CNY
Year on year, growth in earnings per share excluding extraordinary items dropped -11.11%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| EPS growth(5 years) | 3.30 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 8.42 |
